MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
series d preferred...
$9,301,200
Proceeds from issuance or
sale of common stock
$6,391,655
Proceeds from issuance of
series e preferred...
$6,250,000
Proceeds from issuance of
notes payable
$1,335,875
Net cash provided by
financing activities
$14,452,686
Canceled cashflow
$8,826,044
Net increase
(decrease) in cash
$4,574,154
Canceled cashflow
$9,878,532
Payment on note payables
$7,111,548
Payment of redemption of
series c preferred...
$1,713,570
Cash in lieu of shares
$926
Loss on impairment of
goodwill
$11,512,000
Loss on
extinguishment of note payable
$5,384,719
Change in fair value of
series d derivative...
$3,809,333
Loss on issuance of
preferred stock and...
$3,674,329
Change in fair value of
series e derivative...
$1,539,014
Loss on
extinguishment of series c...
$196,244
Amortization of debt discount
$124,084
Stock-based compensation
$74,267
Loss on disposal of
property and equipment
-$17,283
Depreciation and
amortization
$15,170
Net cash used in
operating activities
-$9,678,390
Effect of exchange rate
changes on cash
-$200,142
Canceled cashflow
$26,346,443
Net loss
-$14,032,342
Change in fair value of
series d warrant...
$10,377,638
Change in fair value of
series e warrant...
-$4,486,847
Change in fair value of
subscription agreement...
$3,127,962
Accounts payable
-$1,093,655
Gain on forgiveness
of accounts...
$944,694
Net periodic
pension benefit cost
-$619,399
Accrued expenses
-$580,032
Accounts receivable
$268,685
Deferred offering costs
$225,000
Prepaid expenses and
other assets
$128,360
Inventory
$73,720
Investor receivable
$50,000
Change in fair value of
contingent warrant...
$16,499
Back
Back
Cash Flow
source: myfinsight.com
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)